Zynex Emerges From Bankruptcy With New Ownership Structure

Zynex ( (ZYXIQ) ) just unveiled an announcement.

Zynex emerged from Chapter 11 proceedings on an unspecified Effective Date by entering a $10 million senior secured term loan maturing April 20, 2034, which will automatically convert into common stock once obligations are met or payments under a 2026 non-prosecution agreement are completed, and is secured by substantially all company and subsidiary assets with customary covenants. On the Effective Date, the company’s prior DIP facility and $60 million of 5.00% Convertible Senior Notes due 2026 were discharged, all existing equity interests and incentive-plan shares were canceled, and 1,000 new common shares were issued to Altivera Medical Holdings LLC as sole shareholder, alongside a revamped board structure and amended charter and bylaws that authorize up to 1,000,000 common shares and reset shareholder and board governance, materially reshaping ownership and control for stakeholders.

In connection with its reorganization, Zynex replaced its former capital stack with a new equity base concentrated in a single sponsor and a term loan that is designed to equitize over time, meaning legacy shareholders were wiped out while creditors and the new sponsor now effectively control the recapitalized company. The governance changes, including new directors at both the plan sponsor and company level, updated voting rules, and streamlined board and shareholder procedures, are likely to give Altivera tighter oversight and flexibility as Zynex attempts to stabilize post-bankruptcy and operate with reduced leverage and simplified securities.

The most recent analyst rating on (ZYXIQ) stock is a Hold with a $0.05 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXIQ Stock Forecast page.

Spark’s Take on ZYXIQ Stock

According to Spark, TipRanks’ AI Analyst, ZYXIQ is a Underperform.

The score is driven primarily by distressed financial performance (declining revenue, losses, negative equity/leverage risk) and strongly bearish technicals (price far below moving averages and negative MACD). Valuation is not meaningfully supportive due to negative earnings and no dividend, while the earnings call outlines remediation efforts but confirms significant ongoing financial strain.

To see Spark’s full report on ZYXIQ stock, click here.

More about Zynex

Zynex operates in the medical technology sector, focusing on therapeutic devices and related healthcare solutions. The company serves patients and providers with products designed to manage pain and rehabilitative needs, positioning itself in a specialized segment of the broader medical devices market. Its capital structure and governance are critical to sustaining operations in a regulated, reimbursement-driven industry.

Average Trading Volume: 149,740

Technical Sentiment Signal: Sell

Current Market Cap: $1.58M

See more data about ZYXIQ stock on TipRanks’ Stock Analysis page.